MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.06
+0.12 (+1.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.94
Open7.85
Bid5.31 x 1100
Ask8.30 x 1400
Day's Range7.78 - 8.15
52 Week Range3.31 - 9.87
Volume684,422
Avg. Volume629,935
Market Cap326.632M
Beta3.45
PE Ratio (TTM)N/A
EPS (TTM)-0.74
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.17
Trade prices are not sourced from all markets
  • GlobeNewswire13 hours ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares of its common stock to a new director and a new employee, with a grant date of September 19, 2018. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

  • GlobeNewswire21 days ago

    Marinus Pharmaceuticals to Present at the Baird Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer will present a company overview at the Baird 2018 Healthcare Conference on Thursday, September 6, 2018 at 2:00 p.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswire24 days ago

    Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplingerlast month

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • GlobeNewswirelast month

    Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F. Smith, Chief Financial Officer will present a company overview at the Wedbush/PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 4:15 p.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today
    Motley Fool2 months ago

    Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today

    The small biopharma announced second-quarter 2018 results and gave a business update.

  • Associated Press2 months ago

    Marinus Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. Marinus Pharmaceuticals shares have declined 14 percent since the beginning of the year. The stock has nearly ...

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results

    RADNOR, Pa., Aug. 02, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided ...

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 50,000 shares of its common stock to a new employee, with a grant date of July 27, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • Benzinga2 months ago

    Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

    The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...

  • ACCESSWIRE2 months ago

    Free Technical Research on Marinus Pharma and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.

  • Harry Boxer’s four health-care stocks to watch
    MarketWatch2 months ago

    Harry Boxer’s four health-care stocks to watch

    In focus: Arbutus Biopharma, Marinus Pharmaceuticals, Neptune Technologies & Bioressources and OPKO Health.

  • TheStreet.com2 months ago

    Pfizer Doesn't Look Fundamentally or Technically Strong

    The best-looking trading group right now is the small oil stocks, but even those have thinned out after a few days of strong action. There are also a few biotech names making an effort to turn, but that's sparse, too. PFE also said that it's going to suspend drug-price increase that went into effect July 1 and will keep them on hold there until President Donald Trump unveils his plan to strengthen the U.S. health-care system.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marinus ...

  • ACCESSWIRE3 months ago

    Free Technical Reports on MannKind and Three Additional Biotech Equities

    This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • Benzinga4 months ago

    Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation

    Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg ...

  • ACCESSWIRE4 months ago

    Mayo Clinic-Backed NMTC Could Be Worth 3X This Year

    For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery first: costly and invasive. This kind of event could put a lot of eyeballs on NMTC, and the stock has room to run as it goes through its first price discovery period.

  • Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
    Motley Fool4 months ago

    Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today

    The tiny biopharma is back on the upswing following an analyst upgrade.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...